189 related articles for article (PubMed ID: 34729910)
1. Investigating interactions between chloroquine/hydroxychloroquine and their single enantiomers and angiotensin-converting enzyme 2 by a cell membrane chromatography method.
Jia Q; Fu J; Liang P; Wang S; Wang Y; Zhang X; Zhou H; Zhang L; Lv Y; Han S
J Sep Sci; 2022 Jan; 45(2):456-467. PubMed ID: 34729910
[TBL] [Abstract][Full Text] [Related]
2. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
3. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
Fantini J; Chahinian H; Yahi N
Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32405156
[TBL] [Abstract][Full Text] [Related]
4. Understanding the binding mechanism for potential inhibition of SARS-CoV-2 Mpro and exploring the modes of ACE2 inhibition by hydroxychloroquine.
Choudhury M; Dhanabalan AK; Goswami N
J Cell Biochem; 2022 Feb; 123(2):347-358. PubMed ID: 34741481
[TBL] [Abstract][Full Text] [Related]
5. Chloroquine and Hydroxychloroquine Interact Differently with ACE2 Domains Reported to Bind with the Coronavirus Spike Protein: Mediation by ACE2 Polymorphism.
Badraoui R; Adnan M; Bardakci F; Alreshidi MM
Molecules; 2021 Jan; 26(3):. PubMed ID: 33525415
[TBL] [Abstract][Full Text] [Related]
6. COVID-19, Chloroquine Repurposing, and Cardiac Safety Concern: Chirality Might Help.
Lentini G; Cavalluzzi MM; Habtemariam S
Molecules; 2020 Apr; 25(8):. PubMed ID: 32316270
[TBL] [Abstract][Full Text] [Related]
7. Cell membrane chromatography for the analysis of the interaction between chloroquine and hydroxychloroquine with ACE2 receptors.
Fu J; Jia Q; Zhou H; Zhang L; Wang S; Liang P; Lv Y; Han S
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jan; 1162():122469. PubMed ID: 33310480
[TBL] [Abstract][Full Text] [Related]
8. Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV Spike pseudotyped virus.
Wang N; Han S; Liu R; Meng L; He H; Zhang Y; Wang C; Lv Y; Wang J; Li X; Ding Y; Fu J; Hou Y; Lu W; Ma W; Zhan Y; Dai B; Zhang J; Pan X; Hu S; Gao J; Jia Q; Zhang L; Ge S; Wang S; Liang P; Hu T; Lu J; Wang X; Zhou H; Ta W; Wang Y; Lu S; He L
Phytomedicine; 2020 Dec; 79():153333. PubMed ID: 32920291
[TBL] [Abstract][Full Text] [Related]
9. The molecular dynamics of possible inhibitors for SARS-CoV-2.
Irani AH; Steyn-Ross DA; Steyn-Ross ML; Voss L; Sleigh J
J Biomol Struct Dyn; 2022; 40(20):10023-10032. PubMed ID: 34229582
[TBL] [Abstract][Full Text] [Related]
10. Screened antipsychotic drugs inhibit SARS-CoV-2 binding with ACE2 in vitro.
Lu J; Hou Y; Ge S; Wang X; Wang J; Hu T; Lv Y; He H; Wang C
Life Sci; 2021 Feb; 266():118889. PubMed ID: 33310043
[TBL] [Abstract][Full Text] [Related]
11. An Updated Review on Betacoronavirus Viral Entry Inhibitors: Learning from Past Discoveries to Advance COVID-19 Drug Discovery.
Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
Curr Top Med Chem; 2021; 21(7):571-596. PubMed ID: 33463470
[TBL] [Abstract][Full Text] [Related]
12. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection.
Fantini J; Di Scala C; Chahinian H; Yahi N
Int J Antimicrob Agents; 2020 May; 55(5):105960. PubMed ID: 32251731
[TBL] [Abstract][Full Text] [Related]
13. Repositioning of histamine H
Ge S; Wang X; Hou Y; Lv Y; Wang C; He H
Eur J Pharmacol; 2021 Apr; 896():173897. PubMed ID: 33497607
[TBL] [Abstract][Full Text] [Related]
14. Potential antiviral activity of isorhamnetin against SARS-CoV-2 spike pseudotyped virus in vitro.
Zhan Y; Ta W; Tang W; Hua R; Wang J; Wang C; Lu W
Drug Dev Res; 2021 Dec; 82(8):1124-1130. PubMed ID: 33847382
[TBL] [Abstract][Full Text] [Related]
15. Tetracycline as an inhibitor to the SARS-CoV-2.
Zhao TY; Patankar NA
J Cell Biochem; 2021 Jul; 122(7):752-759. PubMed ID: 33619758
[TBL] [Abstract][Full Text] [Related]
16. Affinity binding of COVID-19 drug candidates (chloroquine/hydroxychloroquine) and serum albumin: Based on photochemistry and molecular docking.
Hu LY; Yuan Y; Wen ZX; Hu YY; Yin MM; Hu YJ
J Photochem Photobiol B; 2023 Mar; 240():112667. PubMed ID: 36753782
[TBL] [Abstract][Full Text] [Related]
17. Chiral distinction between hydroxychloroquine enantiomers in binding to angiotensin-converting enzyme 2, the forward receptor of SARS-CoV-2.
Aiello F; Balzano F; Uccello Barretta G; D'Acquarica I; Mazzoccanti G; Agranat I
J Pharm Biomed Anal; 2024 Jan; 237():115770. PubMed ID: 37879140
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
Fantini J; Chahinian H; Yahi N
Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32862840
[TBL] [Abstract][Full Text] [Related]
19. Docking study of chloroquine and hydroxychloroquine interaction with RNA binding domain of nucleocapsid phospho-protein - an
Amin M; Abbas G
J Biomol Struct Dyn; 2021 Aug; 39(12):4243-4255. PubMed ID: 32469265
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the Modulatory Effect of Hydroxychloroquine on ACE2 Activity: New Insights in relation to COVID-19.
Tichauer JE; Soto D; Andresen M
Biomed Res Int; 2021; 2021():6614000. PubMed ID: 34337036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
